BING Z CARTER

TitleProfessor
InstitutionMD Anderson
DepartmentLeukemia
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Carter BZ, Mak PY, Tao W, Zhang Q, Ruvolo V, Kuruvilla VM, Wang X, Mak DH, Battula VL, Konopleva M, Jabbour EJ, Hughes PE, Chen X, Morrow PK, Andreeff M. Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells. Mol Cancer Ther. 2022 Jun 01; 21(6):879-889. PMID: 35364607.
      Citations:    Fields:    Translation:HumansAnimalsCells
    2. Post SM, Ma H, Malaney P, Zhang X, Aitken MJL, Mak PY, Ruvolo VR, Yasuhiro T, Kozaki R, Chan LE, Ostermann LB, Konopleva M, Carter BZ, DiNardo C, Andreeff MD, Khoury JD, Ruvolo PP. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica. 2022 Jun 01; 107(6):1311-1322. PMID: 34732043.
      Citations:    Fields:    Translation:HumansAnimalsCells
    3. Chen Q, Deng S, Deng M, Shi Y, Zhong M, Ding L, Jiang Y, Zhou Y, Carter BZ, Xu B. Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways. Exp Hematol Oncol. 2022 Apr 16; 11(1):23. PMID: 35429966.
      Citations:    
    4. Maiti A, Carter BZ, Andreeff M, Konopleva MY. Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway. Clin Lymphoma Myeloma Leuk. 2022 Apr 06. PMID: 35490155.
      Citations:    Fields:    
    5. Wang Y, Carter BZ, Li Z, Huang X. Application of machine learning methods in clinical trials for precision medicine. JAMIA Open. 2022 Apr; 5(1):ooab107. PMID: 35178503.
      Citations:    
    6. Yamatani K, Ai T, Saito K, Suzuki K, Hori A, Kinjo S, Ikeo K, Ruvolo V, Zhang W, Mak PY, Kaczkowski B, Harada H, Katayama K, Sugimoto Y, Myslinski J, Hato T, Miida T, Konopleva M, Hayashizaki Y, Carter BZ, Tabe Y, Andreeff M. Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML. Transl Oncol. 2022 Apr; 18:101354. PMID: 35114569.
      Citations:    
    7. Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi PL, Mak D, Ruvolo V, Tan L, Cidado J, Drew L, Andreeff M. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica. 2022 01 01; 107(1):58-76. PMID: 33353284.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    8. Carter BZ, Tao W, Mak PY, Ostermann LB, Mak D, McGeehan G, Ordentlich P, Andreeff M. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML. Blood. 2021 10 28; 138(17):1637-1641. PMID: 34232981.
      Citations: 2     Fields:    Translation:HumansAnimals
    9. Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173. PMID: 34424319.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    10. Jiang X, Jiang L, Cheng J, Chen F, Ni J, Yin C, Wang Q, Wang Z, Fang D, Yi Z, Yu G, Zhong Q, Carter BZ, Meng F. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia. J Transl Med. 2021 03 21; 19(1):117. PMID: 33743723.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    11. Lovat F, Gasparini P, Nigita G, Larkin K, Byrd JC, Minden MD, Andreeff M, Carter BZ, Croce CM. Loss of expression of both miR-15/16 loci in CML transition to blast crisis. Proc Natl Acad Sci U S A. 2021 03 16; 118(11). PMID: 33836616.
      Citations: 3     Fields:    Translation:Humans
    12. Shi YF, Liu L, He LL, Ye J, Lin ZJ, Yuan DL, Deng MM, Fang ZH, Carter BZ, Xu B. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway. Cell Death Dis. 2020 07 22; 11(7):555. PMID: 32699295.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    13. He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Biomed Pharmacother. 2020 Sep; 129:110390. PMID: 32563150.
      Citations: 5     Fields:    Translation:HumansCells
    14. Wang X, Mak PY, Mu H, Tao W, Rao A, Visweswaran R, Ruvolo V, Pachter JA, Weaver DT, Andreeff M, Xu B, Carter BZ. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia. Mol Cancer Ther. 2020 08; 19(8):1636-1648. PMID: 32404407.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    15. Beeharry N, Landrette S, Gayle S, Hernandez M, Grotzke JE, Young PR, Beckett P, Zhang X, Carter BZ, Andreeff M, Halene S, Xu T, Rothberg J, Lichenstein H. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 11 26; 3(22):3661-3673. PMID: 31751472.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    16. Chen F, Sun J, Yin C, Cheng J, Ni J, Jiang L, Wang Q, Yu G, Wei Y, Liu X, Sun J, Carter BZ, Jiang X. Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation. Bone Marrow Transplant. 2020 04; 55(4):740-748. PMID: 31645666.
      Citations: 12     Fields:    Translation:Humans
    17. Carter BZ, Mak PY, Mu H, Wang X, Tao W, Mak DH, Dettman EJ, Cardone M, Zernovak O, Seki T, Andreeff M. Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model. Haematologica. 2020 05; 105(5):1274-1284. PMID: 31371419.
      Citations: 7     Fields:    Translation:AnimalsCells
    18. Boddu P, Carter BZ, Verstovsek S, Pemmaraju N. SMAC mimetics as potential cancer therapeutics in myeloid malignancies. Br J Haematol. 2019 04; 185(2):219-231. PMID: 30836448.
      Citations: 13     Fields:    Translation:Humans
    19. Carter BZ, Mak PY, Wang X, Tao W, Ruvolo V, Mak D, Mu H, Burks JK, Andreeff M. An ARC-Regulated IL1ß/Cox-2/PGE2/ß-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML. Cancer Res. 2019 03 15; 79(6):1165-1177. PMID: 30674535.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    20. Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ. Disruption of Wnt/ß-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 15; 24(10):2417-2429. PMID: 29463558.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    21. Goethe E, Carter BZ, Rao G, Pemmaraju N. Glioblastoma and acute myeloid leukemia: malignancies with striking similarities. J Neurooncol. 2018 Jan; 136(2):223-231. PMID: 29196926.
      Citations: 2     Fields:    Translation:HumansCells
    22. Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M. Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther. 2017 06; 16(6):1133-1144. PMID: 28270436.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    23. Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I. Therapeutic Molecular Targetingof 15-Lipoxygenase-1 in Colon Cancer. Mol Ther. 2008 May; 16(5):886-892. PMID: 28178489.
      Citations: 1     Fields:    
    24. Lan X, Zhao C, Chen X, Zhang P, Zang D, Wu J, Chen J, Long H, Yang L, Huang H, Carter BZ, Wang X, Shi X, Liu J. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms. J Hematol Oncol. 2016 11 25; 9(1):129. PMID: 27884201.
      Citations: 9     Fields:    Translation:Humans
    25. Carter BZ, Andreeff M. Eradication of CML stem cells. Oncoscience. 2016; 3(11-12):313-315. PMID: 28105453.
      Citations: 2     
    26. Fang ZH, Wang SL, Zhao JT, Lin ZJ, Chen LY, Su R, Xie ST, Carter BZ, Xu B. miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways. Cell Death Dis. 2016 09 22; 7(9):e2371. PMID: 27899822.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    27. Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Huang X, Cortes J, Kantarjian H, Konopleva M, Andreeff M. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016 09 07; 8(355):355ra117. PMID: 27605552.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    28. Zhou HS, Carter BZ, Andreeff M. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer Biol Med. 2016 Jun; 13(2):248-59. PMID: 27458532.
      Citations: 58     Fields:    
    29. Carter BZ, Mak PY, Chen Y, Mak DH, Mu H, Jacamo R, Ruvolo V, Arold ST, Ladbury JE, Burks JK, Kornblau S, Andreeff M. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NF?B/IL1ß signaling network. Oncotarget. 2016 Apr 12; 7(15):20054-67. PMID: 26956049.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    30. Jiang X, Wang Z, Ding B, Yin C, Zhong Q, Carter BZ, Yu G, Jiang L, Ye J, Dai M, Zhang Y, Liang S, Zhao Q, Liu Q, Meng F. The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients. Oncotarget. 2015 Oct 20; 6(32):33612-22. PMID: 26384351.
      Citations: 11     Fields:    Translation:HumansCells
    31. Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 2015 Oct 13; 6(31):30487-99. PMID: 26431162.
      Citations: 24     Fields:    Translation:HumansCells
    32. Chen X, Shi X, Zhao C, Li X, Lan X, Liu S, Huang H, Liu N, Liao S, Zang D, Song W, Liu Q, Carter BZ, Dou QP, Wang X, Liu J. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. Oncotarget. 2014 Oct 15; 5(19):9118-32. PMID: 25193854.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    33. Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau SM, Kantarjian H, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia. Br J Haematol. 2014 Nov; 167(3):376-84. PMID: 25079338.
      Citations: 15     Fields:    Translation:HumansCells
    34. Fidler JM, An J, Carter BZ, Andreeff M. Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102. Cancer Chemother Pharmacol. 2014 May; 73(5):961-74. PMID: 24619497.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    35. Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM, Mu H, Tibes R, Yao H, Coombes KR, Jacamo RO, McQueen T, Kornblau SM, Andreeff M. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst. 2014 Feb; 106(2):djt440. PMID: 24526787.
      Citations: 31     Fields:    Translation:HumansCells
    36. Carter BZ, Mak DH, Wang Z, Ma W, Mak PY, Andreeff M, Davis RE. XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells. Leuk Res. 2013 Aug; 37(8):974-9. PMID: 23669290.
      Citations: 6     Fields:    Translation:HumansCells
    37. Katragadda L, Carter BZ, Borthakur G. XIAP antisense therapy with AEG 35156 in acute myeloid leukemia. Expert Opin Investig Drugs. 2013 May; 22(5):663-70. PMID: 23586880.
      Citations: 7     Fields:    Translation:HumansAnimals
    38. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M, Kornblau SM. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 2012 Jul 05; 120(1):173-80. PMID: 22645176.
      Citations: 48     Fields:    Translation:HumansCells
    39. Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis. 2011 Jan; 16(1):67-74. PMID: 20938744.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    40. Le XF, Mao W, Lu Z, Carter BZ, Bast RC. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer. 2010 Nov 01; 116(21):4980-90. PMID: 20629079.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    41. Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller E, Andreeff M, Kornblau SM. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood. 2011 Jan 20; 117(3):780-7. PMID: 21041716.
      Citations: 27     Fields:    Translation:HumansCells
    42. Carter BZ, Mak DH, Cortes J, Andreeff M. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Semin Hematol. 2010 Oct; 47(4):362-70. PMID: 20875553.
      Citations: 10     Fields:    Translation:HumansCells
    43. Carter BZ, Mak DH, Schober WD, Koller E, Pinilla C, Vassilev LT, Reed JC, Andreeff M. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood. 2010 Jan 14; 115(2):306-14. PMID: 19897582.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    44. Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther. 2009 Sep; 8(9):2509-16. PMID: 19723894.
      Citations: 17     Fields:    Translation:HumansCells
    45. Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol. 2009 Oct 01; 27(28):4741-6. PMID: 19652057.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    46. Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I. Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther. 2008 May; 16(5):886-92. PMID: 18388920.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    47. Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC, Andreeff M. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood. 2008 Apr 01; 111(7):3742-50. PMID: 18187663.
      Citations: 49     Fields:    Translation:HumansCells
    48. Mak DH, Schober WD, Chen W, Heller J, Andreeff M, Carter BZ. Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin. Leuk Lymphoma. 2007 Apr; 48(4):774-85. PMID: 17454637.
      Citations: 8     Fields:    Translation:HumansCells
    49. Sah NK, Munshi A, Hobbs M, Carter BZ, Andreeff M, Meyn RE. Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):852-9. PMID: 17011457.
      Citations: 12     Fields:    Translation:HumansCells
    50. Milella M, Konopleva M, Precupanu CM, Tabe Y, Ricciardi MR, Gregorj C, Collins SJ, Carter BZ, D'Angelo C, Petrucci MT, Foà R, Cognetti F, Tafuri A, Andreeff M. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood. 2007 Mar 01; 109(5):2121-9. PMID: 17077328.
      Citations: 16     Fields:    Translation:HumansCells
    51. Carter BZ, Mak DH, Shi Y, Schober WD, Wang RY, Konopleva M, Koller E, Dean NM, Andreeff M. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle. 2006 Oct; 5(19):2223-9. PMID: 16969080.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    52. Gyurkocza B, Plescia J, Raskett CM, Garlick DS, Lowry PA, Carter BZ, Andreeff M, Meli M, Colombo G, Altieri DC. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst. 2006 Aug 02; 98(15):1068-77. PMID: 16882944.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    53. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff M. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006 Jul 15; 108(2):630-7. PMID: 16556893.
      Citations: 59     Fields:    Translation:HumansCells
    54. Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T, Chen W, Andreeff M. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood. 2006 Feb 15; 107(4):1555-63. PMID: 16254145.
      Citations: 34     Fields:    Translation:HumansCells
    55. Carter BZ, Gronda M, Wang Z, Welsh K, Pinilla C, Andreeff M, Schober WD, Nefzi A, Pond GR, Mawji IA, Houghten RA, Ostresh J, Brandwein J, Minden MD, Schuh AC, Wells RA, Messner H, Chun K, Reed JC, Schimmer AD. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood. 2005 May 15; 105(10):4043-50. PMID: 15687241.
      Citations: 31     Fields:    Translation:HumansCells
    56. Carter BZ, Wang RY, Schober WD, Milella M, Chism D, Andreeff M. Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Cell Cycle. 2003 Sep-Oct; 2(5):488-93. PMID: 12963850.
      Citations: 16     Fields:    Translation:HumansCells
    57. Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, Milella M, Sung HG, Reed JC, Andreeff M. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood. 2003 Dec 01; 102(12):4179-86. PMID: 12920030.
      Citations: 33     Fields:    Translation:HumansCells
    58. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood. 2002 May 01; 99(9):3461-4. PMID: 11964319.
      Citations: 30     Fields:    Translation:HumansCells
    59. Carter BZ, Li SC, Li YT. Ceramide glycanase from the earthworm, Lumbricus terrestris. Biochem J. 1992 Jul 15; 285 ( Pt 2):619-23. PMID: 1637351.
      Citations: 5     Fields:    Translation:AnimalsCells
    60. Carter BZ, Malter JS. Regulation of mRNA stability and its relevance to disease. Lab Invest. 1991 Dec; 65(6):610-21. PMID: 1753708.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    61. Li YT, Carter BZ, Rao BN, Schweingruber H, Li SC. Synthesis of neoglycoconjugates using oligosaccharide transferring activity of ceramide glycanase. J Biol Chem. 1991 Jun 15; 266(17):10723-6. PMID: 2040590.
      Citations: 3     Fields:    Translation:Animals
    62. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Science Translational Medicine. 8.
    63. Targeting survivin in leukemia. Oncology Reviews. 1:195-204.
    64. The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients. Oncotarget. 6:33612-33622.
    65. Iap family of proteins as therapeutic targets for acute myeloid leukemia. 151-173.
    66. Molecular cloning and characterization of mouse glutatmonesynthetase gene. FASEB Journal. 10.
    67. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network. Oncotarget. 7:20054-20067.
    68. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms. Journal of Hematology and Oncology. 9.
    69. The ozanam clinic in new orleans. Journal of Investigative Medicine. 44.
    70. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 6:30487-30499.
    71. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia. Cancer Biology and Medicine. 13:248-259.
    72. Eradication of CML stem cells. Oncoscience. 3:313-315.
    CARTER's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (277)
    Explore
    _
    Co-Authors (36)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _